Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Gynecologic Cancer
Final OS Analysis Confirms Benefit of Pembrolizumab Plus Chemotherapy With or Without Bevacizumab for First-Line Treatment of Cervical Cancer
By
Phoebe Starr
ASCO 2023 Highlights
,
Cervical Cancer
,
Gynecologic Cancer
,
Women's Health
August 2023, Vol 14, No 4
Chicago, IL—The addition of the PD-1 inhibitor pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in a substantial and clinically meaningful improvement in overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the phase 3 KEYNOTE-826 trial.
Read Article
Jemperli Plus Chemotherapy Now FDA Approved for Front-Line Treatment of dMMR or MSI-H Endometrial Cancer
FDA Approvals, News & Updates
,
Endometrial Cancer
,
Gynecologic Cancer
August 2023, Vol 14, No 4
On
July 31, 2023
, the FDA approved a new indication for dostarlimab-gxly (Jemperli; GlaxoSmithKline), a PD-1 inhibitor, in combination with carboplatin and paclitaxel, followed by single-agent dostarlimab, for primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H).
Read Article
Study Shows Health Insurance Status Mediates Racial and Ethnic Inequities in Advanced-Stage Cervical Cancer
Disparities in Cancer Care
,
Cervical Cancer
,
Gynecologic Cancer
June 2023, Vol 14, No 3 - Online Only
Health insurance coverage mediated racial and ethnic inequities among patients with advanced-stage cervical cancer, according to findings from a recent retrospective, cross-sectional, population-based study.
Read Article
Jemperli Receives Regular FDA Approval for Advanced Endometrial Cancer
FDA Approvals, News & Updates
,
Gynecologic Cancer
,
Endometrial Cancer
April 2023, Vol 14, No 2
On
February 9, 2023
, the FDA approved dostarlimab-gxly (Jemperli; GlaxoSmithKline) for the treatment of adult patients with mismatch repair-deficient, recurrent or advanced endometrial cancer, as determined by an FDA-approved test, whose disease has progressed on or following a previous platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.
Read Article
Nivolumab Active in HPV-Positive Gynecologic Cancers
By
Charles Bankhead
Gynecologic Cancer
December 2017, Vol 8, No 5
Chicago, IL—Treatment with nivolumab (Opdivo) led to durable responses and stable disease in a majority of women with relapsed or metastatic cancers caused by human papillomavirus (HPV) infection, according to the results of a phase 1/2 clinical trial—CheckMate-358.
Read Article
Higher Readmission Rates After Surgery Not Always Bad in Ovarian Cancer
By
Charles Bankhead
Gynecologic Cancer
June 2017, Vol 8, No 3
National Harbor, MD—A higher readmission rate after surgery had a significant association with improved survival for patients with ovarian cancer, according to 2 studies reported at the 2017 Society of Gynecologic Oncology meeting.
Read Article
Olaparib Maintenance Has Large Progression-Free Survival Advantage in Relapsed Ovarian Cancer with BRCA Mutation
By
Charles Bankhead
Gynecologic Cancer
June 2017, Vol 8, No 3
National Harbor, MD—A randomized clinical trial of olaparib strengthened the PARP (poly ADP-ribose polymerase) inhibitor’s role as maintenance therapy for patients with ovarian cancer and
BRCA
mutation, demonstrating dramatic improvement in progression-free survival (PFS) versus placebo.
Read Article
New Vaccine Shows Monumental Survival Impact in Metastatic Cervical Cancer
By
Charles Bankhead
Gynecologic Cancer
June 2017, Vol 8, No 3
National Harbor, MD—Patients with recurrent metastatic cervical cancer surpassed all historical standards for 1-year survival when treated with an investigational immunotherapy targeting human papillomavirus (HPV) infection.
Read Article
Rubraca’s Benefit in Ovarian Cancer Hinges on Platinum Status, Previous Therapy
By
Charles Bankhead
Gynecologic Cancer
June 2017, Vol 8, No 3
National Harbor, MD—Patients with relapsed high-grade ovarian cancer with
BRCA
mutation derived the greatest benefit from the poly ADP-ribose polymerase (PARP) inhibitor rucaparib (Rubraca) if their disease remained platinum sensitive, a new analysis of a large phase 2 clinical trial showed, as reported at the 2017 Society of Gynecologic Oncology meeting.
Read Article
Opioid Use Decreases in Gynecologic Cancer Surgery with Liposomal Bupivacaine
By
Charles Bankhead
Gynecologic Cancer
June 2016, Vol 7, No 5
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma